An interventional study of Botulinum toxin type A and Focal Extracorporeal Shock Wave Therapy (ESWT) in Post-Stroke Spasticity and Spastic Equinovarus Foot, sponsored by María Belén Martínez Luna. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by María Belén Martínez Luna · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Muscle Spasticity with a site in Spain — 4 open to participants now, 5 under way, none of them phase 3. Muscle Spasticity · Spain.
Among the 37 studies in Muscle Spasticity with a site in Spain, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2024, is one of 20 with no phase, and was the 36th registered.
622 studies on the registry are indexed under Muscle Spasticity; 128 are open to participants now.
Browse Muscle Spasticity studies →4 of the 37 studies in Muscle Spasticity with a site in Spain are open now. Recruiting first, the newest first:
Universidad Pontificia de Salamanca · Sites in Spain
Ages 18–65
Ipsen · Sites in Spain, United States, Austria and 11 more countries
Ages 18–70
Teresa Mateu Campos · Sites in Spain
Ages 18+
University of Oviedo · Sites in Spain
Ages 18+ · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 1 · Phase 4 2
First in 2009; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is above the median of 36 across 473 interventional studies indexed under Muscle Spasticity.
Median enrollment 38 across the 26 interventional studies, 110 across the 11 observational. Of the 29 that completed or were terminated, 3 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 37 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with María Belén Martínez Luna as lead sponsor.
María Belén Martínez Luna has 1 study filed under Muscle Spasticity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 37 studies in Muscle Spasticity with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Spastic equinovarus foot is the most common lower limb motor impairment after stroke and has a significant impact on gait, mobility, and quality of life. Botulinum toxin type A (BoNT-A) is considered the first-line treatment for focal post-stroke spasticity. Extracorporeal shock wave therapy (ESWT) has shown promising results as an adjunctive treatment; however, the optimal timing for its administration in combination with BoNT-A remains unknown.
This prospective, randomized, evaluator-blinded clinical trial aims to determine whether focal ESWT administered before or after BoNT-A injection is more effective than BoNT-A alone in patients with chronic post-stroke spastic equinovarus foot. Sixty-nine participants will be randomly allocated to one of three treatment groups: (1) BoNT-A alone; (2) one session of focal ESWT immediately before BoNT-A injection; or (3) one session of focal ESWT two weeks after BoNT-A injection. The primary outcome is spasticity measured with the Modified Ashworth Scale (MAS). Secondary outcomes include the Modified Tardieu Scale, passive ankle range of motion, muscle strength (MRC), 10-Meter Walk Test (10MWT), Functional Ambulation Classification (FAC), pain (VAS), Patient-Specific Assessment Scale (PSAS), muscle echogenicity using the Heckmatt scale, and muscle stiffness assessed by real-time elastography. Assessments will be performed at baseline and during follow-up through week 54.
Stroke is one of the leading causes of long-term disability worldwide. Lower limb spasticity develops in a substantial proportion of stroke survivors, with the spastic equinovarus foot representing the most common gait pattern impairment. This condition negatively affects walking ability, balance, activities of daily living, and quality of life.
Botulinum toxin type A (BoNT-A) is considered the standard treatment for focal post-stroke spasticity. Nevertheless, its clinical effect is temporary and additional therapeutic strategies are needed to optimize and prolong treatment benefits. Extracorporeal shock wave therapy (ESWT) is a non-invasive intervention that has demonstrated beneficial effects on muscle tone, muscle stiffness, pain, and functional recovery. Experimental and clinical evidence suggests that ESWT may enhance the effects of BoNT-A, although the optimal timing of ESWT administration has not yet been established.
This study is a prospective, randomized, single-blind, three-arm clinical trial conducted at the Department of Physical and Rehabilitation Medicine of Hospital Clínico San Carlos (Madrid, Spain). Participants with chronic post-stroke spastic equinovarus foot who meet the eligibility criteria will be randomly assigned to one of three treatment groups:
Group A: BoNT-A injection alone.
Group B: One session of focal ESWT immediately before BoNT-A injection.
Group C: BoNT-A injection followed by one session of focal ESWT two weeks later. PROYECTO TESIS.docx
The primary outcome is lower limb spasticity measured using the Modified Ashworth Scale (MAS). Secondary outcomes include the Modified Tardieu Scale, passive ankle dorsiflexion range of motion, muscle strength measured by the Medical Research Council (MRC) scale, gait performance assessed by the 10-Meter Walk Test (10MWT) and Functional Ambulation Classification (FAC), pain assessed by the Visual Analogue Scale (VAS), patient-reported function using the Patient-Specific Assessment Scale (PSAS), muscle echogenicity using the Heckmatt scale, and muscle stiffness evaluated by real-time elastography. PROYECTO TESIS.docx
Clinical and ultrasound evaluations will be performed at baseline and at 4, 12, 24, 28, 42, and 54 weeks after treatment. The findings are expected to clarify whether the timing of focal ESWT administration influences the effectiveness of BoNT-A in the treatment of post-stroke spastic equinovarus foot and may contribute to optimizing rehabilitation protocols.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the control group receive botulinum toxin type A (Botox®, onabotulinumtoxinA) alone, injected under ultrasound guidance into the spastic lower-limb muscles according to the study protocol. No extracorporeal shock wave therapy is administered.
Drug: Botulinum toxin type A
Participants receive one session of focal extracorporeal shock wave therapy immediately before botulinum toxin type A (Botox®, onabotulinumtoxinA) injection into the spastic lower-limb muscles.
Drug: Botulinum toxin type A · Device: Focal Extracorporeal Shock Wave Therapy (ESWT)
Participants receive botulinum toxin type A (Botox®, onabotulinumtoxinA) injection into the spastic lower-limb muscles, followed by one session of focal extracorporeal shock wave therapy two weeks later.
Drug: Botulinum toxin type A · Device: Focal Extracorporeal Shock Wave Therapy (ESWT)
Botulinum toxin type A (Botox®, onabotulinumtoxinA) injected under ultrasound guidance into the spastic lower-limb muscles according to each participant's clinical presentation and the study protocol. Injection sites and doses are individualized based on the pattern and severity of spasticity.
Also known as: OnabotulinumtoxinA
One session of focal extracorporeal shock wave therapy (ESWT) applied to the spastic calf muscles according to the study protocol using standardized treatment parameters.
Change in spasticity assessed by the Modified Ashworth Scale (MAS)
Change in lower-limb spasticity measured using the Modified Ashworth Scale (MAS) after treatment.
Time frame: Baseline, 4, 12, 24, 28, 42 and 54 weeks.
Modified Tardieu Scale
Change in lower-limb spasticity assessed using the Modified Tardieu Scale, including the quality of muscle reaction and the angle of muscle reaction at different stretching velocities.
Time frame: Baseline, 4, 12, 24, 28, 42 and 54 weeks
Change in passive ankle dorsiflexion range of motion
Passive ankle dorsiflexion range of motion will be measured in degrees using a goniometer, with the knee flexed and extended. Higher values indicate greater ankle dorsiflexion.
Time frame: Baseline, 4, 12, 24, 28, 42 and 54 weeks
Change in lower-limb muscle strength assessed by the Medical Research Council Scale
Muscle strength will be assessed using the Medical Research Council Scale, ranging from 0 to 5, where 0 indicates no visible muscle contraction and 5 indicates normal muscle strength.
Time frame: Baseline, 4, 12, 24, 28, 42 and 54 weeks
Change in gait speed assessed by the 10-Meter Walk Test
Gait speed will be assessed using the 10-Meter Walk Test and expressed in meters per second. Higher gait speed indicates better walking performance.
Time frame: Baseline, 4, 12, 24, 28, 42 and 54 weeks
Change in muscle echogenicity assessed by the Heckmatt Scale
Muscle echogenicity will be assessed by ultrasound using the Heckmatt Scale, ranging from grade I to grade IV. Higher grades indicate increased muscle echogenicity and greater structural muscle alteration.
Time frame: Baseline, 4, 12, 24, 28, 42 and 54 weeks
Change in pain intensity assessed by the Visual Analogue Scale
Pain intensity associated with spasticity will be assessed using a Visual Analogue Scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Time frame: Baseline, 4, 12, 24, 28, 42 and 54 weeks
Change in patient-reported function assessed by the Patient-Specific Assessment Scale
Patient-reported difficulty with activities affected by spastic equinovarus foot will be assessed using the Patient-Specific Assessment Scale. The evaluated activities include maintaining balance, walking quickly, climbing stairs, descending stairs, and putting on shoes.
Time frame: Baseline, 4, 12, 24, 28, 42 and 54 weeks
Plan to share: No — Individual participant data will not be shared because the study consent and ethics approval do not include public sharing of de-identified individual participant data
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 23 months after the start.
Of 226 non-industry interventional studies with no phase under Muscle Spasticity, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 37. This study's planned 23 months is above that.
Counting every sponsor, half of 234 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.